|
Balance Sheet Cash Flow Statement 2910 7th St. Berkeley, CA 94710 CA Tel. 510-204-7200 Toll Free 800-246-9662 Fax 510-644-0537 |
Type: Public
On the web:
http://www.xoma.com
Employees:
335
Employee growth: 7.7%
XOMA doesn't want to toil in anonymity. Instead, the company pairs with larger drug firms to develop and market its products, primarily monoclonal antibodies. XOMA receives royalties from biotech giant Genentech on FDA-approved product Lucentis, a treatment for age-related macular degeneration that Genentech developed with technology licensed from XOMA. The company's in-house team is developing its lead candidate, diabetes treatment XOMA 052. It has additional collaborative agreements with Novartis (to develop cancer therapies) and the National Institutes of Health (to find treatments for bioterror threat botulinum).
Key numbers for fiscal year ending December, 2008:
Sales: $68.0M
One year growth: (19.3%)
Net income: ($45.2)M
Officers:
Chairman, President, and CEO: Steven B. Engle
VP Finance and CFO: Fred Kurland
VP Operations; Head, Biodefense: Robert S. (Rob) Tenerowicz
Competitors:
Abbott Labs
Amgen
Pfizer
